Letter: Daunomycin (NSC-82151) and adriamycin (NSC-123127): a hypothesis concerning antitumor activity and cardiotoxicity.

Suppr

超能文献

作者信息

Adamson R H

出版信息

Cancer Chemother Rep. 1974 May-Jun;58(3):293-4.

PMID:4841712

Abstract

摘要

相似文献

Letter: Daunomycin (NSC-82151) and adriamycin (NSC-123127): a hypothesis concerning antitumor activity and cardiotoxicity.

Cancer Chemother Rep. 1974 May-Jun;58(3):293-4.

Another hypothesis concerning the antitumor activity and cardiotoxicity of daunorubicin (NSC-82151) and adriamycin (NSC-123127).

Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):258-9.

The cardiotoxicity of adriamycin and daunomycin in children.阿霉素和柔红霉素对儿童的心脏毒性。

Cancer. 1976 Feb;37(2 Suppl):1070-8. doi: 10.1002/1097-0142(197602)37:2+<1070::aid-cncr2820370814>3.0.co;2-6.

Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).通过与顺二氨二氯铂（NSC - 119875）或柔红霉素（NSC - 82151）联合使用增强ICRF - 159（NSC - 129943）对早期L1210白血病的抗肿瘤效果。

Cancer Chemother Rep 2. 1974 Mar;4(1):45-52.

[Cardiotoxicity of anthracycline cytostatic agents--a proposal for routine monitoring and supportive therapy].[蒽环类细胞毒性药物的心脏毒性——常规监测及支持治疗建议]

Vnitr Lek. 1991 Feb;37(2):151-9.

Editorial: Adriamycin and the heart.

Lancet. 1974 Jun 29;1(7870):1325.

Toxicologic screening of daunorubicin (NSC-82151), adriamycin (NSC-123127), and their derivatives in rats.

Cancer Chemother Rep. 1975 Jul-Aug;59(4):707-15.

On the reported lack of effectiveness of daunomycin (NSC-82151) and adriamycin (NSC-123127) on solid tumors.

Cancer Chemother Rep. 1972 Aug;56(4):431-2.

Daunomycin- and adriamycin-N-(2-hydroxypropyl)methacrylamide copolymer conjugates; toxicity reduction by improved drug-delivery.

Cancer Treat Rev. 1987 Dec;14(3-4):319-27. doi: 10.1016/0305-7372(87)90024-7.

Comparison of daunorubicin (NSC-83142) with adriamycin (NSC-123127) in the treatment of late-stage childhood solid tumors.

Cancer Chemother Rep. 1974 Sep-Oct;58(5 Pt 1):671-6.

引用本文的文献

Cancer chemotherapy: new developments and changing concepts.癌症化疗：新进展与观念转变

Drugs. 1980 Nov;20(5):375-97. doi: 10.2165/00003495-198020050-00003.

Detection and quantification of mitoxantrone in human organs. A case report.人器官中米托蒽醌的检测与定量。病例报告。

Cancer Chemother Pharmacol. 1984;13(1):67-8. doi: 10.1007/BF00401451.

A phase I trial of ametantrone acetate (NSC-287513).醋酸氨茴环素（NSC-287513）的I期试验。

Invest New Drugs. 1985;3(4):383-8. doi: 10.1007/BF00170762.

Mitoxantrone: an overview of safety and toxicity.米托蒽醌：安全性与毒性概述

Invest New Drugs. 1985;3(2):123-32. doi: 10.1007/BF00174159.

Structural modification study of anthracyclinones: synthesis and biological activity of several derivatives of eta-pyrromycinone.

Pharm Res. 1992 Jun;9(6):739-42. doi: 10.1023/a:1015891102895.

Cardiotoxic effects of antitumor agents.抗肿瘤药物的心脏毒性作用。

Cancer Chemother Pharmacol. 1978;1(1):24-34. doi: 10.1007/BF00253143.

Anthracyclines--modern tumour-inhibiting agents.

Folia Microbiol (Praha). 1978;23(2):152-61. doi: 10.1007/BF02915316.

Antineoplastic drugs: clinical pharmacology and therapeutic use.抗肿瘤药物：临床药理学与治疗应用

Drugs. 1978 Jul;16(1):46-87. doi: 10.2165/00003495-197816010-00003.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验